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Introduction
Epidemiological and biological studies have clearly demonstrated that approximately 15 mucosal human papillomaviruses (HPVs), referred to as high-risk HPV types, are the etiological agents of cervical cancer (zur Hausen, 2000) . Among these, HPV16 is the most frequent type associated to cervical cancer worldwide (Clifford et al., 2003) . The products of two early genes, E6 and E7, act as major oncoproteins in HPV-induced carcinogenesis (Munger et al., 2004) . Since the viral DNA replication is totally dependent on host cellular machinery, these oncoproteins have developed a number of mechanisms to drive cells into S phase (Munger et al., 2004) . In a normal situation, the exposure of quiescent cells to mitogens gives rise to activation of cyclin/cyclin dependent kinase (CDK) complexes, with concomitant dissociation and/or degradation of CDK inhibitors, such as p21 WAF1 , a key regulator of the G1/S transition (Ekholm and Reed, 2000; Kaldis and Aleem, 2005) . The transcription of p21 WAF1 gene is known to be regulated by several cellular factors, including the tumor suppressor protein p53 (el-Deiry et al., 1993) . Upon DNA damage, accumulation of p53 leads to increased p21 WAF1 levels, inducing a G1 arrest and allowing DNA reparation before replication (Sherr and McCormick, 2002) . Furthermore, it has been shown that p21 WAF1 can bind to PCNA (proliferating-cell nuclear antigen), an essential DNA replication factor, and this binding is sufficient for the inhibition of DNA replication based on simian virus 40 (Chen et al., 1995) . HPV16 E6 mediates the interaction between the ubiquitin protein ligase E6AP and p53, promoting degradation of the latter via the proteasome pathway (Kao et al., 2000) . Thus, HPV16 E6 expressing cells in presence of DNA damages do not accumulate p21 WAF1 and continue to proliferate (Mantovani and Banks, 2001) . We have previously presented several lines of evidence that E6 protein has an additional p53-independent mechanism to down-regulate p21 WAF1 expression and promote cell cycle progression. In fact, E6
from the benign cutaneous HPV1 and a HPV16 E6 mutant that are unable to target p53 for degradation, were still competent to inhibit p21 WAF1 transcription and induce cellular proliferation (Malanchi et al., 2004 (Malanchi et al., , 2002 . However, this E6 p53-independent mechanism still remains to be elucidated. Few reports describe that the product of Sal2 gene, p150 Sal2 , acts in part as a p53-independent positive regulator of p21 WAF1 transcription (Li et al., 2004) . Interestingly, p150 Sal2 (Li et al., 2001 ) has been found to be targeted by the oncoprotein large T antigen from the mouse polyomavirus.
Here, we show that HPV16 E6 is able to bind to and inactivate the transcriptional functions of p150 Sal2 in several experimental models. Virology 417 (2011) 443-448 Results HPV16 E6 inhibits p21 WAF1 transcription in the absence of p53
We have previously observed that HPV16 is able to alter the regulation of the restriction point in the G1 phase of the cell cycle by down-regulation of p21 WAF1 expression by a mechanism that is independent of p53 inactivation (Malanchi et al., 2004 (Malanchi et al., , 2002 . To investigate whether this E6 p53-independent mechanism affects p21 WAF1 mRNA transcription, the activity of the p21 WAF1 promoter linked to a luciferase reporter gene was evaluated in primary human fibroblast (POF) in the presence of a siRNA targeting p53 or a scramble control. We observed that the activity of the p21 WAF1 promoter declined with increasing concentrations of HPV16 E6 wild type in presence and absence of p53 (Figs. 1A and B ). In addition, HPV16 E6 was able to inhibit p21 WAF1 promoter in a human osteosarcoma cell line (SaOS-2) that is p53 null (Fig. 1C) .
We next analyzed the ability of two HPV16 E6 mutants, L110Q and G130V, to modulate p21. It has been previously reported that both mutants are unable to bind E6AP and induce p53 degradation (Liu et al., 1999) . The mutation G130V was still able to inhibit the p21 promoter in a dose dependent-manner, whereas the mutation L110Q totally abolished the suppression of the p21 WAF1 promoter by HPV16 E6 (Fig. 1B) . Besides p53, another cellular protein, p150 Sal2 , positively regulates p21 WAF1 expression (Li et al., 2004 The ability of HPV16 E6 to inhibit p21 WAF1 expression correlates with its affinity for p150
Sal2
We next determined whether the down-regulation of p21
WAF1
promoter activity in absence of p53 by HPV16 E6 could be due to its ability to associate with p150
Sal2
. We first performed immunoprecipitation experiments. HPV16 E6 fused with hemagglutinin (HA) at the C terminal (HPV16 E6HA) was stably expressed in SaOS-2 cells, which were subsequently transfected with a plasmid expressing Flag-p150 Sal2 fusion protein. As shown in Fig. 2A , an anti HA antibody efficiently immunoprecipitated p150 Sal2 protein in HPV16
E6-HA SaOS-2 cells transfected with p150-Flag, but not in the mock cells. Also an anti-Flag antibody efficiently immunoprecipitated HPV16 E6 protein (Fig. 2B) , providing an additional evidence that the two proteins can interact. Based on the fact that HPV16 E6 G130V mutant is still able to inhibit p21 WAF1 expression in a p53-independent mechanism, we hypothesized that this mutant has also retained the ability to interact with p150 Sal2 , while this property
should not be shared with the HPV16 E6 L110Q mutant. To confirm this hypothesis, we next analyzed the ability of the two HPV16 E6 mutants, L110Q and G130V, to bind p150 Sal2 in a GST-pull down assay. The L110Q mutation completely abolished the binding to p150 Sal2 (Fig. 2C ), while G130V was still able to interact with p150
, although with reduced efficiency in respect to the HPV16 E6 wild-type protein (Fig. 2C) .
Next we compared the ability of HPV16 E6 wild type and mutants (L110Q and G130V) to down-regulate the expression of the endogenous p21 WAF1 gene. POFs were transduced with recombinant retroviruses expressing wild type, L110Q or G130V HPV16 E6 (Fig. 3A) and the endogenous mRNA levels of p21 WAF1 were determined in all cell lines by quantitative RT-PCR (Fig. 3B) Several independent studies reported that the interaction of E6 protein with cellular factors often results in their rapid degradation (Mantovani and Banks, 2001 ). Therefore, we next determined whether HPV16 E6 decreases the intracellular levels of p150 Sal2 in
POFs. Unexpectedly, p150 Sal2 levels were clearly elevated in POFs transduced with the HPV16 E6 wild-type retrovirus (Fig. 4A ). This accumulation was less evident or completely undetectable in cells expressing the HPV16 E6 G130V or L110Q mutant, respectively (Fig. 4A ). HPV16 E6 induced p150 Sal2 accumulation also in the p53-null SaOS-2 cells (Fig. 4B) , demonstrating that the stabilization of p150 Sal2 is not a consequence of the E6-mediated p53 inactivation. In addition, the HPV16 E6-mediated p150 Sal2 accumulation was detected in HPV-positive cervical cancer-derived cell lines SiHa (HPV16), CaSki (HPV16) and HeLa (HPV18), but not in the cervical cancer line C33A that is HPV-negative (Fig. 4C ). Gene silencing of HPV16 E6 and E7 expression in CaSki cells resulted in a strong reduction of p150 Sal2 levels (Fig. 4D) . Importantly, we observed that (C) HPV16 E6 wild type, G130V and L110Q proteins were expressed as a GST fusion in BL21 E. coli strain purified and immobilized on Glutathione-sepharose beads. Purified recombinant proteins were incubated with POF extracts. Beads were washed and captured proteins were analyzed by SDS-PAGE (12% gel) and immunoblotting with anti-p150 Sal2 or
anti-GST antibodies. The input represents 10% of the protein extract used for incubation. . Together these data show that HPV16 E6 is able to prevent the binding of p150
Sal2 on the p21 WAF1 promoter.
Discussion
We have previously observed that HPV16 is able to alter the regulation of the restriction point in the G1 phase of the cell cycle by down-regulation of p21 WAF1 transcript by a mechanism that is independent of p53 inactivation (Malanchi et al., 2004 (Malanchi et al., , 2002 . Here, we show that HPV16 E6 binds, stabilizes and inactivates the transcription factor p150 Sal2 , which is implicated in the positive regulation of the p21 WAF1 promoter (Li et al., 2004 protein from a DNA tumor virus, the large T antigen of mouse polyomavirus (Li et al., 2001 ). This interaction was characterized in a cellular assay, which allowed the identification of p150 Sal2 as a negative regulator of viral replication (Li et al., 2001) . Since viral replication is dependent on the host DNA replication machinery and G 1 -to-S progression, the inhibition of p150
Sal2
, and consequently down-regulation of p21 WAF1 , represent a key event in the life cycle of the virus. Therefore, based on the polyomavirus model, a similar scenario could be envisaged for HPV16. The importance of the neutralization of p21 WAF1 for HPV16 life cycle is underlined by the existence of several virus-mediated mechanisms to block the functions of the CDK inhibitor. In fact, in addition to the ability of E6 to repress p21 WAF1 transcription with p53-dependent and -independent mechanisms, it has been shown that the other major HPV16 oncoprotein, E7, binds p21
WAF1
, preventing its interaction with CDK2 and PCNA (Funk et al., 1997; Jones et al., 1997) .
The existence of two distinct mechanisms of HPV16 E6 to repress p21 WAF1 transcription is not surprising. In fact, it is very likely that p150 Sal2 and p53 activate p21 WAF1 transcription in different circumstances. In this scenario, E6 would be able to inhibit p21 WAF1 transcription independently of the situation of the infected cell and guaranteeing a constant and efficient viral DNA replication. In addition, it is very likely that p150 Sal2 regulates the transcription of additional cellular genes encoding proteins, which may play a negative role in the HPV life cycle, and therefore needs to be neutralized. Our data indicate that HPV16 E6 induces the accumulation of an inactive form of p150 Sal2 . Interestingly, p150 Sal2 levels were found to be elevated in synovial sarcomas (Nielsen et al., 2003) . In light of our findings, we could speculate that the accumulation of p150 Sal2 in this pathological setting reflects the loss of its function. In summary, we describe here a new mechanism for HPV16 E6 down-regulation of p21 WAF1 transcription, independently of p53 in which inactivation of p150 Sal2 is required. It is likely that a similar mechanism of inactivation of p21 WAF1 expression occurs in other cancers non-and virally induced.
Materials and methods
Cell culture
SaOS-2, SiHa, CaSki, HeLa, C33A, Phoenix and primary human oral fibroblast (POF) were grown in DMEM supplemented with 10% fetal calf serum. Recombinant retroviruses, infections, doubling population counting and colony assays were performed as previously described (Caldeira et E6 and E7 in CaSki was achieved by transient transfection using the following siRNA 5′ UUAAAUGACAGCUCAGAGG 3′.
Plasmid constructs
The retroviral vectors pBabe-puro and pBabe-neo were described previously (Morgenstern and Land, 1990) , while the pLXSN construct was obtained from Clontech (Palo Alto, CA, USA). The open reading frames of HPV16 E6 wild-type and the two mutants G130V and L110Q (kindly provided by Elliot Androphy, Indiana University, Indianapolis, IN, USA) were amplified by PCR and cloned in pBabe-neo, pLXSN or pGEX-4T1 expression vector (Amersham Biosciences, Piscataway, NJ, USA) with or without the hemagglutinin (HA) tag sequence at the 5′ end. Full-length and serial deletions of p21 WAF1 promoter in pJFACT1
were kindly provided by Bert Vogelstein (el-Deiry et al., 1993) and Xiao-Fan Wang (Duke University Medical Center, Durham, NC, USA). The p53 pRetroSuper construct was used as previously described (Accardi et al., 2006 chromatography and visualized by autoradiography. Quantification was performed by excising the products and liquid scintillation counting.
Biochemical analyses
Preparation of total protein cellular extracts and immunoblotting were performed as previously described (Accardi et al., 2006 , and anti-HA (Roche, Mannheim, Germany). All densitometry analyses were performed using the BIORAD phosphor-imager. For the immunoprecipitation, cleared lysates were incubated overnight at 4°C with anti-Flag or anti-HA. After addition of protein A/G plus agarose (Santa Cruz Biotechnology), immunoprecipitates were collected and subjected to a 15% or a 10% SDS-PAGE and transferred to a membrane.
The GST pull down assays were performed as previously described (Caldeira et al., 2003) .
ChIP assay was performed using previously described protocol (Zannetti et al., 2010) 
Quantitative RT-PCR
Total RNA extraction and cDNA synthesis were performed as previously described . Real-time PCR was performed by using the LightCycler® FastStart DNA Master PLUS SYBR Green I kit (Roche, Mannheim, Germany) in a LightCycler fluorescence temperature cycler according to the manufacturer's instructions. Primers used for RT-PCR and real-time PCR are listed in Table 1 (Supplementary material).
Supplementary materials related to this article can be found online at doi:10.1016/j.virol.2011.05.016. 
